LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Total Non-current Assets
All assets not expected to be converted to cash within one year.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets broadly unchanged from a year ago
Total non-current assets stood at $4.41M at the end of Q1 FY2026, down 1.3% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at +1044.9% a year.
Context
- Total non-current assets amounted to 1.1% of total assets at the end of Q1 FY2026, down 22.1 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -1.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 4.5M USD
- Year-over-year change
- -3.3%
- 3-year CAGR
- +1044.9%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.5M | -3.3% |
| FY2024 | 2024-12-31 | 4.66M | +20139.1% |
| FY2023 | 2023-12-31 | 23K | +666.7% |
| FY2022 | 2022-12-31 | 3K | — |
Total Non-current Assets vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 total non-current assets of $4.41M is the 8th highest of the 10 companies compared; the peer median is $22.52M.
- Its year-over-year change of -1.3% is the 7th highest of 10, against a peer median of +16.4%.
- Total non-current assets amounts to 1.1% of total assets for LBRX, versus a peer median of 2.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $15.36B | +103156.5% | -0.1% | 16.1% | |
| Sep 2026 | $525.73M | +106.7% | +84.6% | 29.3% | |
| Jun 2026 | $404.03M | +74.5% | +40.6% | 34.9% | |
| Mar 2026 | $91.56M | +588.3% | +176.1% | 21.9% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $22.52M | +6.9% | -4.6% | 2.1% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $12.9M | +16.4% | +245.9% | 2.6% |
| Mar 2026 | $7.13M | -15.0% | +62.2% | 2.6% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $4.41M | -1.3% | +1044.9% | 1.1% |
| Mar 2026 | $3.04M | -88.2% | -70.3% | 1.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $443K | -76.5% | -76.3% | 0.3% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $22.52M | +16.4% | +40.6% | 2.6% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.